Catalog No.
Product Name
Application
Product Information
Citations
-
CB1/CB2 Agonist
BAY 38-7271 is a highly potent and selective agonist of the cannabinoid CB1 and CB2 receptors, exhibiting binding affinities with Kis of 1.85 nM for the human CB1 receptor and 5.96 nM for the CB2 receptor. This compound demonstrates significant neuroprotective properties, making it a valuable tool for research in neuropharmacology and the therapeutic potential of cannabinoid systems. Its activation of CB1 and CB2 receptors can aid in understanding various neurological disorders and the roles of endocannabinoids in pain management and inflammation. -
Cannabinoid Receptor Agonist
APP-FUBINACA is a potent cannabinoid receptor agonist derived from phenylalaninamide-based indazole-3-carboxamide. This compound displays neurostimulatory properties, making it a valuable tool for research involving cannabinoid signaling pathways and their impact on neurological functions. Its applications include studies on pain modulation, mood disorders, and the neurobiological effects of cannabinoids. -
Cannabinoid Receptor Agonist
CB2R agonist 3 is a selective agonist of cannabinoid receptor 2 (CB2R), exhibiting an EC50 of 0.37 μM. This compound modulates immune responses, making it valuable for research focused on inflammation, pain management, and neurological disorders. Its ability to selectively target CB2R allows for the investigation of cannabinoid pathways in various biological systems. -
CB2 Receptor Agonist
HU 433 is a synthetic cannabinoid that functions as a selective agonist of the CB2 receptor. It demonstrates significant anti-inflammatory and neuroprotective properties through its interaction with CB2 receptors. This compound is valuable for research applications focused on neuroinflammation and retinal disorders, facilitating a deeper understanding of these conditions and their potential treatments. -
Cannabinoid Receptor Agonist
JTE 7-31 is a selective agonist of peripheral cannabinoid receptors, designed to minimize central nervous system side effects. It demonstrates potent immunomodulatory, anti-inflammatory, and anti-allergic properties, making it a valuable tool for research applications focused on inflammation and immune responses. Additionally, JTE 7-31 exhibits inhibitory effects on nephritis, further supporting its utility in studies related to kidney health. -
CB2 Ligand
CB2 receptor antagonist 5 is a selective antagonist of the cannabinoid 2 (CB2) receptor, which plays a crucial role in the endocannabinoid system. This compound effectively inhibits CB2 receptor signaling, making it valuable for studying pain modulation, inflammation, and immune responses. It serves as a useful tool in research aimed at understanding the therapeutic potential of CB2 receptor modulation in various diseases. -
CB2 Receptor Agonist
CB2 receptor agonist 7 is a selective agonist for the cannabinoid 2 (CB2) receptor, exhibiting permeability across the blood-brain barrier. This compound demonstrates significant biological activity in modulating cannabinoid receptor signaling, making it a valuable tool for studying the role of CB2 receptors in neuroinflammation and pain management research. Its unique properties enable exploration of therapeutic applications for various neurological disorders. -
CB1/CB2 Ligand
PSB-SB-1203 is a dual ligand for CB1 and CB2 receptors, functioning as a CB1 antagonist and a CB2 agonist (CB1 Ki 0.244 μM; CB2 Ki 0.210 μM; EC50 0.054 μM). This compound demonstrates significant potential for research in the fields of obesity and cancer, providing valuable insights into the role of cannabinoid receptors in these conditions. Its unique mechanism of action may help to elucidate therapeutic pathways and contribute to the development of targeted treatments. -
CB2 Inverse Agonist
SMM-189 is a potent and selective inverse agonist of the cannabinoid receptor 2 (CB2). This compound demonstrates significant biological activity relevant to the modulation of inflammatory and neuroprotective pathways, making it a valuable tool in the investigation of neurodegenerative disorders and traumatic brain injury. Its selective targeting of the CB2 receptor provides insights into therapeutic approaches for conditions associated with these pathologies. -
CB2 Receptor Agonist
MDA7 is a selective agonist of the cannabinoid receptor 2 (CB2) with an EC50 of 128 nM in human CB2 receptors and 67.4 nM in rat CB2 receptors. It demonstrates strong affinity for both human and rat CB2 receptors, indicated by Ki values of 422 nM and 238 nM, respectively. MDA7 exhibits notable analgesic effects in rat models, making it a valuable tool for researching cannabinoid signaling and pain modulation. -
Cannabinoid
Cannabicitran is a cannabinoid that primarily targets the endocannabinoid system. It has been shown to decrease intraocular pressure in rabbit models, indicating potential therapeutic applications in the treatment of glaucoma and other ocular conditions. This compound may also be useful in studying cannabinoid receptor pathways and their biological effects. -
Cannabinoid Receptor Antagonist
CE-178253 benzenesulfonate is a cannabinoid receptor 1 (CB1) antagonist that effectively interferes with cannabinoid signaling in the central nervous system. Its inhibition of CB1 receptors makes it a valuable tool for studying the roles of endocannabinoids in various physiological processes and potential therapeutic applications for addiction and neurological disorders. This compound serves as an important reagent for researchers investigating cannabinoid receptor modulation and its implications in pharmacology. -
CB2 Receptor Agonist
L-759656 is a selective agonist of the cannabinoid CB2 receptor, demonstrating a Ki of 11.8 nM for the human receptor. This compound effectively inhibits Forskolin-stimulated cyclic AMP production in Chinese Hamster Ovary (CHO) cells, with an EC50 value of 3.1 nM. L-759656 serves as a valuable tool for investigating immune-related and inflammatory diseases. -
Stable Isotope
Olivetol-d9 is a deuterium-labeled derivative of Olivetol, a naturally occurring phenol primarily found in lichens and produced by specific insects. It functions as a competitive inhibitor of cannabinoid receptors CB1 and CB2, thus influencing endocannabinoid signaling pathways. Additionally, Olivetol-d9 has inhibitory effects on the cytochrome P450 enzymes CYP2C19 and CYP2D6, making it a valuable tool in pharmacological research and studies related to cannabinoid biology. -
CB1/2 Receptor Agonist
CB1/2 Receptor-1 is a potent agonist of the CB1 and CB2 receptors, playing a significant role in modulating cannabinoid signaling pathways. This compound exhibits key biological activities relevant to angiogenesis research, offering valuable insights into vascular growth and development mechanisms. It serves as an essential tool for investigators exploring the therapeutic potential of cannabinoid receptors in various biological contexts. -
CB2 Receptor Agonist
CB2 receptor agonist 4 is a highly selective agonist for the cannabinoid receptor type 2 (CB2) with an EC50 of 13.99 nM. This compound demonstrates minimal activity against cannabinoid receptor type 1, ensuring specificity in its biological effects. CB2 receptor agonist 4 is intended for use in research related to pain modulation and immune-related diseases, making it valuable for studies investigating therapeutic strategies in these areas. -
CB1 Receptor Probe
IDFP (iso-Prdodecylfluorophosphonate) is a chemical affinity probe specifically targeting the cannabinoid CB1 receptor. This compound is utilized in research to investigate the role of the CB1 receptor in various physiological processes and neurological conditions. Its selective binding properties make IDFP a valuable tool for studying cannabinoid signaling pathways and their implications in pharmacology and therapeutics. -
CB2R Ligand
CB2R ligand-1 (Compound L14) is a highly selective ligand for the Cannabinoid type 2 receptor (CB2R), demonstrating a Ki of 0.16 nM, indicating significant potency over CB1R. This compound is valuable for research applications involving positron emission tomography (PET) imaging, particularly in the study of neurodegenerative diseases, inflammation, and cancer. Its specificity provides a useful tool for elucidating the role of CB2R in various pathological conditions. -
Cannabinoid Mimetics
1'-Naphthoyl-2-methylindole is a cannabinoid mimetic that interacts with cannabinoid receptors, demonstrating inhibitory effects on [3H]Win 55212-2 binding. At a concentration of 3 μM, it inhibits 34% of binding, providing utility in studies focused on cannabinoid receptor regulation and signaling pathways. This compound is valuable for research applications investigating the pharmacological effects of cannabinoids and their potential therapeutic uses. -
Cannabinoid Receptors Agonist
MDMB-FUBICA is a potent agonist of the cannabinoid receptors, exhibiting psychoactive properties that support its use in various research applications. This compound is particularly relevant for the study of electronic cigarette formulations and their interactions with cannabinoid pathways. Its unique pharmacological profile makes it a valuable tool for investigating the effects of cannabinoids on neural activity and behavior. -
CETP Inhibitor/CB1 Agonist
BI-5756 is a selective CETP inhibitor and cannabinoid receptor 1 (CB1) agonist. It promotes a significant increase in HDL-C levels while reducing LDL-C levels, thereby improving lipid profiles. Additionally, BI-5756 enhances the function of regulatory T cells and preserves T cell-mediated anti-tumor activity, exhibiting direct anti-proliferative effects on tumor cells. This compound also upregulates the expression of MHC I, MHC II, and CD80 on tumor cells and demonstrates protective effects in graft-versus-host disease. BI-5756 is applicable in research related to oncology, graft-versus-host disease, and metabolic disorders. -
CB2R Probe
CB2R Probe 1 is a fluorescent probe targeting the cannabinoid 2 receptor (CB2R), with an affinity (Ki) of 130 nM. This probe exhibits low cytotoxicity in cancer cell lines, making it suitable for cellular imaging and receptor studies. It is ideal for research applications focused on CB2R-related signaling pathways and their implications in cancer biology. -
Anandamide Analogue
(R)-(+)-Linoleyl-1'-Hydroxy-2'-Propylamide is an analogue of the endogenous cannabinoid receptor ligand anandamide, targeting both CB1 and CB2 receptors. This compound exhibits weak binding affinity to these receptors, with inhibition constants (Kis) measured at 21 μM. Its potential applications in research include studies on cannabinoid signaling pathways and exploring the therapeutic effects of cannabinoid receptor modulation. -
Cannabinoid Receptor Antagonist
Hemopressin (human, mouse) TFA targets the cannabinoid CB1 receptor as a selective inverse agonist. This nonapeptide, derived from the α1-chain of hemoglobin and originally isolated from rat brain homogenates, demonstrates oral bioavailability. Hemopressin TFA has been shown to exert antinociceptive effects in models of inflammatory pain, making it valuable for research in pain management and cannabinoid signaling pathways. -
CB1R/iNOS Antagonist
(Rac)-Zevaquenabant is a potent cannabinoid receptor type 1 (CB1R) and iNOS antagonist, exhibiting a Ki value of 5.7 nM for CB1R. This compound is primarily utilized in studies related to liver fibrosis, providing valuable insights into its pathophysiology and potential therapeutic interventions. Its selective inhibition of CB1R and iNOS pathways makes it a significant tool for investigating cannabinoid signaling and its implications in fibrotic diseases. -
Stable Isotope
2-Arachidonoylglycerol-d11 is a deuterated form of 2-arachidonoylglycerol, a naturally occurring cannabinoid that acts as an endogenous ligand for cannabinoid receptors in the central nervous system. This stable isotope is useful for tracing and quantifying the metabolism of endocannabinoids in various biological studies. Its applications include pharmacokinetic research and studies of cannabinoid signaling pathways. -
CB2R/FAAH Modulator
CB2R/FAAH modulator-2 is a dual-targeting modulator that functions as an agonist of the cannabinoid receptor 2 (CB2R) and an inhibitor of fatty acid amide hydrolase (FAAH). It exhibits Ki values of 10.8 nM for CB2R and 152.9 nM for CB1R, with an IC50 of 6.2 μM for FAAH. This compound is suitable for investigating therapeutic applications in cancer, neurodegenerative diseases characterized by inflammatory processes, and potential impacts on COVID-19 infection pathways. -
CB1 Agonist
Docosatetraenylethanolamide (DEA) is a potent cannabinoid receptor 1 (CB1) agonist. It exhibits significant inhibition of the specific binding of cannabinoid probes to rat synaptosomal membranes, demonstrating a Ki value of 34.4 nM. DEA is valuable in the study of neurological processes and the role of cannabinoids in the nervous system. -
CB2R Agonist
CB2R Agonist 1 is a selective agonist for the cannabinoid receptor subtype 2 (CB2R) with an EC50 of 0.56 µM, demonstrating high affinity and specificity for human CB2R. This compound modulates the production of both pro-inflammatory and anti-inflammatory cytokines, highlighting its potential for immunomodulatory effects. It is a valuable tool for research in inflammation and immune response pathways. -
Cannabinoid Analog
R-2 Methanandamide is a cannabinoid analog that selectively interacts with cannabinoid receptors, exhibiting a Ki value of 119 nM as determined in rat brain membranes. This compound is primarily utilized in research to investigate the effects of cannabinoid signaling on various physiological processes. Its structural similarity to Anandamide enables the exploration of its potential applications in neuropharmacology and the understanding of endocannabinoid system modulation. -
CB1 Receptor Agonist
LBP1 is an orally active CB1 receptor agonist with low brain penetrance. It demonstrates notable anti-allodynic and anti-hyperalgesic properties in rodent models of neuropathic pain. This compound is valuable for research aimed at understanding pain mechanisms and evaluating potential therapeutic strategies targeting cannabinoid receptors. -
CB1 Receptor Agonist
S-2 Methanandamide is a potent agonist of the CB1 receptor, exhibiting an IC50 value of 173 nM in the presence of PMSF. It demonstrates significantly lower activity at the CB2 receptor, with an IC50 value of 8216 nM. This compound is primarily utilized in research applications investigating cannabinoid receptor signaling and the physiological effects of endocannabinoids. -
S1R Antagonist
CM304 free base is a potent antagonist of the sigma-1 receptor (S1R). It enhances the antinociceptive effects of cannabinoid receptor agonists and exhibits anticonvulsant properties, effectively inhibiting convulsions in rat models. This compound is valuable for research applications focusing on pain modulation and seizure management. -
CB1R Inverse Agonist
TC-C 14G is a potent inverse agonist of the Cannabinoid-1 Receptor (CB1R), exhibiting a Ki value of 4 nM and an EC50 of 11 nM for HCB1R. This compound is valuable for research exploring the role of CB1R in various physiological processes and the pathophysiology of diseases related to cannabinoid signaling. Its efficacy in modulating CB1R activity makes it a significant tool for studies focused on neurobiology, appetite regulation, and potential therapeutic interventions. -
CB1 Receptor Antagonist
Amauromine is a selective antagonist of the cannabinoid receptor type 1 (CB1), displaying Ki and Kb values of 178 nM and 66.6 nM, respectively. Its pharmacological profile makes it a valuable tool for exploring the role of CB1 receptors in various physiological processes. Amauromine is applicable in research related to cannabinoid pharmacology, metabolic disorders, and potential therapeutic interventions targeting the endocannabinoid system. -
Dopamine Activator/CB1 Receptor Ligand
BB-22 is a potent CB1 receptor ligand that acts as a dopamine activator. It exhibits a high affinity for CB1 receptors with a Ki value of 0.11 nM and demonstrates effective activation with an EC50 value of 2.9 nM. This compound may be valuable in studying the roles of endocannabinoid and dopaminergic systems in various neurological and psychiatric disorders. -
CB1R Inverse Agonist
CB1R Antagonist 1 is a selective inverse agonist of the cannabinoid-1 receptor (CB1R) with an IC50 value of 4.2 μM. This compound effectively modulates CB1R activity, making it a valuable tool for investigating metabolic processes and obesity-related pathways. Its specificity and potency facilitate research into the therapeutic potential of targeting CB1R in metabolic disorders. -
CB1R Antagonist
BNS808 is a selective antagonist of the cannabinoid-1 receptor (CB1R), demonstrating an IC50 value of 0.8 nM while exhibiting notable selectivity for the CB2 receptor and limited central nervous system penetration. This compound is primarily utilized in research focused on obesity and its related metabolic disorders, including metabolic dysfunction-associated steatotic liver disease (MASLD). BNS808's reduced availability for CNS entry enhances its safety profile and minimizes the potential for drug-drug interactions due to high plasma protein binding. -
CB1 Agonist
CB1/2 agonist 4 serves as a full agonist for the CB1 receptor and a partial agonist for the CB2 receptor, exhibiting EC50 values of 15.09 nM and 1.16 nM, respectively. It demonstrates high affinity for human CB1 and CB2 receptors, with Ki values of 1.1 nM and 4.2 nM. This compound displays notable antinociceptive activity and effectively activates both cannabinoid and TRPV1 receptors, featuring IC50 and EC50 values of 0.8 μM and 0.12 μM, respectively. CB1/2 agonist 4 is valuable for studies exploring cannabinoid receptor functions and their implications in pain modulation. -
CB1/CB2 Receptor Agonists
O-2545 hydrochloride acts as a highly potent agonist for both CB1 and CB2 receptors, exhibiting Ki values of 1.5 nM and 0.32 nM, respectively. This water-soluble compound is valuable for research applications in epilepsy, pain management, and multiple sclerosis. Its selective interaction with cannabinoid receptors makes it a useful tool for exploring therapeutic pathways related to these conditions. -
CB1R Inverse Agonist
MK-5596 is a selective and orally active inverse agonist of the cannabinoid receptor 1 (CB1R), exhibiting an IC50 of 1.0 nM and an EC50 of 5.8 nM. This compound demonstrates significant biological activity in promoting weight loss and appetite suppression. Additionally, MK-5596 exhibits mild inhibitory effects on several cytochrome P450 enzymes, including CYP3A4, CYP2C8, CYP2C9, and CYP2D6, with IC50 values ranging from 3.3 to 18 μM. This reagent is primarily utilized in research focused on obesity and its associated metabolic disorders. -
CB1/2 Inhibitor
AM12814 is a potent and selective inhibitor of cannabinoid receptors CB1 and CB2, demonstrating Ki values of 0.7 nM and 3.4 nM, respectively. This compound effectively inhibits cAMP accumulation and promotes β-arrestin 2 recruitment, mimicking cannabimimetic effects. AM12814 is suitable for research applications related to neurological diseases, including studies on catalepsy. -
CB1 Ligand
O-1812 is a selective cannabinoid receptor type 1 (CB1) ligand, primarily targeting the CB1 receptor involved in the endocannabinoid system. It exhibits weak inhibition of the enzyme amine oxidase (AMT), making it a useful tool in investigations of neuropharmacology. This compound can be applied in research focused on chronic pain, migraines, and inflammation, contributing to the understanding of these conditions at the molecular level. -
CB1 Receptor Antagonist
rel-O-2050 is a neutral antagonist of the cannabinoid CB1 receptor. It effectively inhibits the activity of this receptor, which is implicated in the regulation of appetite and energy balance. Research indicates that rel-O-2050 can decrease food intake in murine models, making it a useful tool for studying cannabinoid signaling and its effects on metabolism and appetite control. -
CB2R Agonist/FAAH Inhibitor
CB2R/FAAH modulator-1 is a potent full agonist of the cannabinoid type 2 receptor (CB2R), exhibiting a binding affinity with a Ki of 14.8 nM for CB2R and 241.3 nM for CB1R. This compound also serves as an inhibitor of fatty acid amide hydrolase (FAAH), demonstrating an IC50 of 4 μM. CB2R/FAAH modulator-1 is effective in modulating cytokine production by decreasing pro-inflammatory cytokines while enhancing anti-inflammatory cytokine levels, making it valuable for research in inflammation and pain modulation. -
CB1 Antagonist
AZD-2207 is a potent antagonist of the cannabinoid receptor CB1, exhibiting high lipophilicity and favorable intestinal permeability in the Caco-2 model. This compound is particularly relevant in research focused on metabolic disorders such as type 2 diabetes and obesity, facilitating investigations into potential therapeutic strategies for these conditions. -
CB1/2 Agonist
CB1/2 Agonist 2 is a potent non-selective cannabinoid ligand that targets the cannabinoid receptors CB1 and CB2. With Ki values of 3.5 nM and 1.2 nM, respectively, it functions as a full agonist at CB1 while acting as a competitive inverse agonist at CB2. This compound demonstrates significant antinociceptive activity, making it a valuable tool for research in pain management and cannabinoid signaling pathways. -
CB1R Allosteric Modulator
CB1R Allosteric Modulator 2 is a potent allosteric inhibitor of the cannabinoid receptor type 1 (CB1R). This compound negatively modulates the functional activity of orthosteric ligands at CB1Rs, acting as a negative allosteric modulator (NAM). Its unique mechanism makes it a valuable tool for studying the effects of cannabinoid signaling and its downstream biological pathways, providing insights into potential therapeutic applications in neurological disorders and metabolic regulation. -
CB1R Modulator
GAT564 is a potent allosteric modulator of the cannabinoid 1 receptor (CB1R), exhibiting EC50 values of 87 nM for cAMP and 320 nM for β-arrestin2. This compound enhances orthosteric ligand binding to hCB1R, indicating its role in modulating receptor activity. In research applications, GAT564 demonstrates significant efficacy as a topical agent, effectively reducing intraocular pressure (IOP) in ocular normotensive murine models of glaucoma. -
E Configuration Of RNB-61
(E)-RNB-61 is an orally active cannabinoid receptor agonist, specifically targeting the CB2 receptor with a Ki range of 0.13 nM to 1.81 nM. This compound exhibits notable renal protective and anti-fibrotic properties, making it a valuable tool for research in renal disease and fibrosis models. Its selective action on the CB2 receptor positions (E)-RNB-61 as a promising candidate for studies investigating the therapeutic potential of cannabinoids in inflammatory and fibrotic conditions.
